Response rate and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes [2]

Annals of Hematology

Volumn 84, Issue 7, 2005, Pages 479-481

  Candoni, A ^a   Raza, A ^b,c   Silvestri, F ^a   Lisak, L ^b,c   Galili, N ^b,c   Mumtaz, M ^b,c   Kikic, F ^a   Fanin, R ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b RUSH UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CIPROFLOXACIN; DEXAMETHASONE; ETANERCEPT; THALIDOMIDE; TOPOTECAN;

ADULT; AGED; BLOOD TRANSFUSION; CANCER PATIENT; CHROMOSOME ANALYSIS; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSE REGIMEN; FEMALE; HEALTH CARE FACILITY; HUMAN; INFECTION; KARYOTYPING; LETTER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; SURVIVAL RATE; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 20944440398     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-1031-7     Document Type: Letter

References (11)

1. Faderl S, Kantarjian HM (2004) Novel therapies for myelodysplastic syndromes. Cancer 101(2):226-241
2. Rosenfeld C, List A (2000) A hypothesis for the pathogenesis of myelodysplastic syndromes: Implications for new therapies. Leukemia 14(1):2-8
3. Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N (2002) Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 16(1):1-6
4. Musto P (2004) Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. Leuk Res 28(4):325-332 10.1016/ j.leukres.2003.08.007
5. Aul C, Giagounidis A, Germing U, Ganser A (2002) Evaluating the prognosis of patients with myelodysplastic syndromes. Ann Hematol 81:485-497
6. Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F, Du Randt M, Kaspar C, Goldberg C, Loew J, Dar S, Gezer S, Venugopal P, Zeldis J (2001) Thalidomide produces transfusion independence in long standing refractory anemias of patients with myelodysplastic syndromes. Blood 98(4):958-965
7. Candoni A, Silvestri F, Buonamici S, Li D, Reddy P, Galili N, Nucifora G, Raza A (2004) Targeted therapies in myelodysplastic syndromes: ASH 2003 Review. Semin Hematol 41(2 Suppl 4):13-20
8. Raza A, Candoni A, Khan U, Lisak L, Tahir S, Silvestri F, Billmeier J, Imran Alvi M, Mumtaz M, Gezer S, Venugopal P, Reddy P, Galili N (2004) Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leuk Lymphoma 45(10):2099-2104
9. Raza A, Buonamici S, Lisak L, Tahir S, Li D, Imran M, Chaudary NI, Pervaiz H, Gallegos JA, Alvi MI, Mumtaz M, Gezer S, Venugopal P, Reddy P, Galili N, Candoni A, Singer J, Nucifora G (2004) Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res 28(8):791-803
10. Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C, Wilkens L, Heinsch M, Willems H, Aivado M, Aul C (2004) Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 18(1):113-119
11. List AF, Kurtin S, Glinsmann-Gibson B, Bellamy W, Buresh A, Mahadevan D, Rimsza L, Waddelton D, Knight RD (2003) Efficacy and safety of CC5013 for treatment of anemia in patients with myelodysplastic syndromes (MDS). Blood 102(11):641